270MO A single-arm, open-label, multicenter phase II study of camrelizumab in patients with recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) who had progressed on ≥2 lines of chemotherapy: CAPTAIN study
Annals of Oncology（2020）
关键词
Nasopharyngeal carcinoma,Phases of clinical research,Chemotherapy,Oncology,Medicine,In patient,Internal medicine,Open label
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要